PRESENT:

Dr S Ramtoola (SR) Consultant Physician, ELHT (Chairperson)
Mrs C Woffindin (CW) Medicines Information Manager, ELHT
Mr V Goodey (VG) Assistant Director of Pharmacy, Clin Service ELHT
Mr N Fletcher (NF) Director of Pharmacy ELHT
Dr L Rogan (LR) Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG
Dr N Amir (NA) Consultant Microbiologist, ELHT
Mr A Gray (AG) Clinical Pharmacist, ELHT
Dr T McKenzie (TM) GP East Lancs
Dr S Jackson (SJ) Clinical Commissioning Group MM Lead, GP EL
Mr J Vaughan (JV) Commissioning Support Pharmacist NHS EL/BwD
Ms J Kenyon (JK) Senior Pharmacist NHS BwD CCG

IN ATTENDANCE:

Ms L Prince Medicines Management Technician, EL CCG
Dr G Perera Consultant Paediatrician, ELHT (for Item 025)

2021/036: APOLOGIES:

Mr U Akram (UA) Pharmacist, Lancashire Care Foundation Trust

Neil Fletcher expressed the Medicines Management Board thanks to Christine for her contributions to the Board over many years and wished her well in her retirement.

2021/037: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2021/038: MINUTES OF FEBRUARY Teams MEETING:

Accepted as a correct record.

2021/039: MATTERS ARISING:

East Lancashire Health Economy Medicines Management Board consists of East Lancashire CCG; BwD CCG and East Lancs Hospitals Trust (ELHT)


2020/015: New Product Request – Relvar Ellipta® & Anoro Ellipta® - more inhalers are now available and LSCMMG are reviewing products, devices and pathways. Include Relvar Ellipta® and Anoro Ellipta® on formulary as an option for secondary care clinicians to access where considered appropriate. The LSCMMG pathways for inhaler products and devices to be brought to ELMMB when available for consideration. Resolved: Relvar Ellipta® & Anoro Ellipta® to be added to formulary as an option for secondary care clinicians. Traffic Light: AMBER

2020/092: Drug Safety Update – Denosumab – Concerns with stopping treatment with denosumab following the drug safety update in August 2020 to be discussed with consultants by directorate pharmacists and brought back to May meeting. VG/AG to coordinate.


2021/016: Goserelin Shared Care Guideline – amended 10.8mg shared care for first dose in primary care accepted for use.

2021/040: LSCMMG CONSULTATIONS (FOR MARCH LSCMMG)

Liothyronine RAG status Review – comments from ELMMB after discussion:-
Recommendation 1 – clarify this means patient’s not already on liothyronine
Recommendation 2 – consider should be Red. Amber not supported by CCGs
Recommendation 3 – agree black
Recommendation 4, 5, 6 – agree
Recommendation 7, 8 – not relevant for existing patients

Primary Care Headache Management Pathway – the pathway for giant cell arteritis may be different in different areas and times of day. Suggest it would be preferable to state ‘refer immediately according to local pathway’.

Oxygen for Cluster Headache – New Medicine Assessment – to support use of oxygen for cluster headache when used in line with headache pathway. Supported by members of ELMMB

Metolazone Amber Proposal – currently red in ELHE and concerns expressed over costs as it is unlicensed. Amber may not be appropriate for all health economies where some may have services in place to prescribe and deliver as red.

Comments to be sent to LSCMMG
2021/041: LSCMMG Recommendations

Rheumatoid Arthritis High Cost Drugs Pathway - Updated – Accepted for use in ELHE.

2021/042: JOINT COMMITTEE OF CCGs COMMISSIONING DECISIONS
None

2021/043: FORMULARY UPDATES

Pantoprazole IV New product request – requested for use on critical care, as a bolus injection, to replace omeprazole infusion during current supply issues with giving sets. SR suggested could consider adopting for the whole trust to replace IV omeprazole infusion on a long term basis. Gastroenterology and surgery directorate pharmacists to discuss with teams for consideration of a long term change to pantoprazole IV and bring proposals to ELMMB.
Resolved: Pantoprazole IV to be included in formulary for critical care use during supply issues with giving sets.

2021/044: NICE RECOMMENDATIONS (from February)

Mepolizumab for treating severe eosinophilic asthma [TA671 fast track] is recommended as an option by NICE. Approved in line with NICE. NHS England Commissioned Traffic Light: RED

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA673) is recommended as an option by NICE. Approved in line with NICE. Cancer Drugs Fund Traffic Light: RED

Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) (TA674) Traffic Light: BLACK

Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal) (TA675) Traffic Light: BLACK

Filgotinib for treating moderate to severe rheumatoid arthritis (TA676) is recommended as an option by NICE. Approved in line with NICE. CCG Commissioned - Blueteq form required Traffic Light: RED
This recommendation brings a cost pressure and also a service pressure as there is a potential for a large number of patients. Potential implications to be scoped out with rheumatologists and estimate of numbers to be sent to CCGs.

Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma (TA677) is recommended as an option by NICE. Approved in line with NICE. Cancer Drugs Fund Traffic Light: RED
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA 678) Traffic Light: BLACK

Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA 679) is recommended as an option by NICE. Approved in line with NICE. CCG Commissioned Traffic Light: GREEN
Concerns expressed that some monitoring information should be provided to GPs. A Lancashire wide piece of work being prepared and will be shared at next meeting.

Trabectedin for the treatment of advanced soft tissue sarcoma (TA185 updated)

2021/045: NICE HIGHLY SPECIALISED TECHNOLOGIES (from February)
Metreleptin for treating lipodystrophy (HST14) Acknowledged
Commissioning arrangements to be considered outside of ELMMB

2021/046: EAMS
Nivolumab with ipilimumab - Treatment of adult patients with inoperable malignant pleural mesothelioma, a type of cancer that affects the lining of the lung. Acknowledged

STANDING ITEMS

2021/047: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES – February 2021 Minutes acknowledged

2021/048: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA FT D & T MINUTES – January 2021 Minutes acknowledged

2021/049: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – October 2020 Minutes acknowledged

2021/050: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – November 2020 Minutes acknowledged

2021/051: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – December 2020 Minutes acknowledged

2021/052: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – January 2021 Minutes acknowledged
EXTRA ITEM: LMWH SWITCH

ELHT will be switching from Enoxaparin as the LMWH (low molecular weight heparin) for prophylaxis of DVT/PE as this will be more cost effective. The planned switch date is 1st May 2020 and updated guidance & information will be brought to next meeting. Tinzaparin will remain in place for treatment doses.

DATE OF NEXT MEETING – Wednesday 21st April 2021 12.30pm via ‘Microsoft Teams’
<table>
<thead>
<tr>
<th>MINUTE NUMBER</th>
<th>DESCRIPTION</th>
<th>ACTION</th>
<th>DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019/131</td>
<td>Treatment Of Vitamin B12 Deficiency Draft – pathway to be developed.</td>
<td>LR/JV</td>
<td>Sept 21</td>
</tr>
<tr>
<td>2020/092</td>
<td>Drug Safety Update – Denosumab Directorate pharmacist to discuss with consultants.</td>
<td>AG/VG</td>
<td>May 21</td>
</tr>
<tr>
<td>2021/044</td>
<td>NICE Recommendations (from February) – Filgotinib (TA676) – implications to be scoped with rheumatology team &amp; estimate of numbers to CCG</td>
<td>VG</td>
<td>April 21</td>
</tr>
<tr>
<td>2021/044</td>
<td>NICE Recommendations (from February) – Dapagliflozin (TA679) – Lancashire wide information to come next meeting</td>
<td>SR</td>
<td>April 21</td>
</tr>
</tbody>
</table>